Watch TMDX. Know when insiders buy.
One email the day a filing lands. Free.
TMDX
TransMedics Group, Inc.
88.14
+2.28 +2.66%
USD · Sep 15, 10:40 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · insiders 60, shorts 42
Insiders, 90 days
+$109K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.1BP/E 22.8DIV YIELD —FCF YIELD 2.59%REV TTM $668.5M +25.8%NET INCOME $151.7M +111.7%NET CASH $296.1M52W 62.04 – 150.42SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $189.9M | +20.7% | 59.6% | $23.7M | $14.7M | −57.9% | 0.41 | $17.3M | $7.1M | $10.2M | Aug 4 |
| Q1 2026 · Mar 31 | $173.9M | +21.2% | 58.2% | $13.3M | $7.3M | −71.5% | 0.20 | $24.5M | $36.7M | −$12.1M | Aug 4 |
| Q4 2025 · Dec 31derived | $160.8M | +32.2% | 58.1% | $21.3M | $105.4M | +1436.9% | 2.59 | $34.5M | $15.5M | $19M | Feb 24 |
| Q3 2025 · Sep 30 | $143.8M | +32.2% | 58.8% | $23.3M | $24.3M | +476.8% | 0.66 | $69.6M | $7.6M | $61.9M | Oct 29 |
| Q2 2025 · Jun 30 | $157.4M | +37.7% | 61.4% | $36.6M | $34.9M | +186.3% | 0.92 | $91.6M | $9.1M | $82.5M | Aug 4 |
| Q1 2025 · Mar 31 | $143.5M | +48.2% | 61.5% | $27.4M | $25.7M | +110.6% | 0.70 | −$2.9M | $27M | −$29.9M | Aug 4 |
| Q4 2024 · Dec 31derived | $121.6M | +49.8% | 59.2% | $8.6M | $6.9M | +70.1% | 0.20 | $19.7M | $13.6M | $6.1M | Feb 24 |
| Q3 2024 · Sep 30 | $108.8M | +63.7% | 55.9% | $3.9M | $4.2M | — | 0.12 | $6.9M | $48.2M | −$41.3M | Oct 29 |
| Q2 2024 · Jun 30 | $114.3M | — | 60.6% | $12.5M | $12.2M | — | 0.35 | $25.7M | $23.8M | $2M | Oct 29 |
| Q1 2024 · Mar 31 | $96.8M | — | 61.9% | $12.4M | $12.2M | — | 0.35 | −$3.4M | $44.2M | −$47.6M | Oct 29 |
| Q4 2023 · Dec 31derived | $81.2M | — | 59.0% | $2.6M | $4M | — | 0.12 | $8.3M | $41.8M | −$33.5M | Feb 24 |
| Q3 2023 · Sep 30 | $66.4M | — | 61.2% | −$28.3M | −$25.4M | — | -0.78 | −$6.9M | $107.7M | −$114.6M | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $605.5M | 59.9% | $108.6M | $190.3M | 31.4% | 4.87 | $192.8M | $59.3M | $133.6M | — | — |
| FY2024 · to Dec 31 | $441.5M | 59.4% | $37.5M | $35.5M | 8.0% | 1.01 | $48.8M | $129.7M | −$80.9M | — | — |
| FY2023 · to Dec 31 | $241.6M | 63.8% | −$28.7M | −$25M | -10.4% | -0.77 | −$13M | $151.8M | −$164.9M | — | — |
| FY2022 · to Dec 31 | $93.5M | 69.8% | −$31.4M | −$36.2M | -38.8% | -1.23 | −$45.8M | $11.9M | −$57.7M | — | — |
| FY2021 · to Dec 31 | $30.3M | 69.9% | −$39.4M | −$44.2M | -146.1% | -1.60 | −$28.9M | $3.5M | −$32.4M | — | — |
| FY2020 · to Dec 31 | $25.6M | 64.9% | −$26.4M | −$28.7M | -112.1% | -1.16 | −$30.3M | $455K | −$30.7M | — | — |
Every number comes from TransMedics Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.